<DOC>
	<DOCNO>NCT02917629</DOCNO>
	<brief_summary>This randomized phase IIb trial study well ACTOplus meet XR work treat patient stage I-IV oral cavity oropharynx cancer undergo definitive treatment . Chemoprevention use drug keep oral cavity oropharynx cancer form come back . The use ACTOplus meet XR may slow disease progression patient oral cavity oropharynx cancer .</brief_summary>
	<brief_title>ACTOplus Met XR Treating Patients With Stage I-IV Oral Cavity Oropharynx Cancer Undergoing Definitive Treatment</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether 14-21 day treatment ACTOplus meet XR result 50 % decrease proliferation index ( Ki-67 ) expression oral cavity/oropharyngeal tumor tissue . SECONDARY OBJECTIVES : I . Compare differences proliferation index ( Ki-67 ) expression baseline post-exposure visually normal appear oral cavity/oropharyngeal tissue . II . Compare immunohistochemical difference apoptosis biomarker cleave caspase 3 baseline post-exposure oral cavity/oropharyngeal adjacent visually normal appear tissue tumor tissue sample . III . Compare immunohistochemical difference baseline post-exposure oral cavity/oropharyngeal tumor tissue sample regard cyclin D1 , p21 biguanide PPAR gamma associate pathway biomarkers ; prospective biomarkers panel include phosphorylated ( p ) AKT , pAMPK , pS6 ( metformin ) , PPAR gamma . IV . Compare immunohistochemical difference baseline post-exposure oral cavity/oropharyngeal tumor tissue sample regard tumor infiltrate immune cell ( effector CD8 [ CD8+IFNg+ ] ) , regulatory CD4 T regulatory ( Treg ) ( CD4+Foxp3+ ) , tumor associate myeloid cell ( CD68 ) , PD1 PD-L1 . V. Compare correlate pre- post-ACTOplus met XR treatment human ribonucleic acid ( RNA ) -sequencing ( seq ) gene analysis total RNA sample oral cavity/oropharyngeal adjacent visually normal appear tissue tumor tissue pre-and post-study treatment . VI . Determine human papillomavirus ( HPV ) status pre-treatment tumor tissue use p16 immunohistochemistry . VII . Compare pre- post-study treatment positron emission tomography ( PET ) /computed tomography ( CT ) scan determine change tumor fluorodeoxyglucose ( FDG ) uptake/metabolism . OUTLINE : Patients randomize 1 2 group . GROUP I : Patients receive ACTOplus meet XR orally ( PO ) daily ( QD ) 14-21 day absence disease progression unacceptable toxicity . Patients may continue ACTOplus meet XR PO QD maximum 25 day end treatment biopsy/surgical treatment delay beyond day 22 . GROUP II : Patients receive placebo PO QD daily 14-21 day .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Participant newly diagnose , histologically confirm , stage IIV squamous cell carcinoma oral cavity oropharynx undergo definitive surgical , radiotherapy , chemoradiation treatment OR Participant lesion oral cavity oropharynx yet biopsied highly suspicious cancer ; ( randomization place hold presence cancer histologically confirm , standard care stag PET/CT scan complete treatment plan establish ; presence cancer confirm , participant consider screen failure ) The participant 's primary tumor accessible biopsy outpatient clinic setting participant willing baseline end study ( day 1526 ) 4 mm punch biopsy tumor adjacent visually normal appear tissue biomarker analysis If participant biopsyconfirmed cancer , baseline biopsy collect tissue biomarker analysis addition prestudy diagnostic biopsy If participant surgical treatment , end study biopsy may collect time surgery unless surgery delay beyond day 26 If participant surgical treatment , end study biopsy collect prior initiation nonsurgical treatment Participant able complete minimum 14 day study agent dose prior initiation definitive treatment cancer Participant schedule end study biopsy within 22 day start study agent within 36 day study screen visit ; ( participant schedule surgical excision tumor surgery delay reason participant start take study agent , study agent dose may extend maximum 25 day without compromise evaluability end study biomarkers ) A standard care stag PET/CT scan perform prior randomization Participant willing able another FDG PET/CT perform within 36 hour day 1526 end study biopsy Eastern Cooperative Oncology Group ( ECOG ) performance status = 0 1 Life expectancy &gt; 6 month Body mass index ( BMI ) &gt; = 18.5 Hemoglobin &gt; = 10 g/dl White blood cell &gt; = 3,000/microliter Platelets &gt; = 100,000/microliter Total bilirubin within normal institutional limit With exception candidate diagnosis Gilbert 's disease case total bilirubin may extend 1.5 x institutional upper limit normal Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) within normal institutional limit Alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) within normal institutional limit Glucose , serum &lt; 200 mg/dL Estimated glomerular filtration rate ( eGFR ) &gt; 45 mL/min use CockcroftGault calculator Participant able swallow tablet whole Participant willing able participate duration study Participant childbearing potential agrees use adequate contraception ( hormonal method continual use minimum 3 month prior study screen visit , barrier method , abstinence ) duration study participation ; ( woman become pregnant suspect pregnant participating study , inform study physician immediately ) NOTE : participant start hormonal therapy purpose meeting eligibility criterion protocol Ability understand willingness sign write informed consent document Participant receive receive form treatment cancer prior complete minimum 14 day study agent dosing ; ( biopsy consider form treatment ) Participant concurrent diagnosis type I type II diabetes treat insulin oral antidiabetic agent ; ( participant whose type II diabetes control diet and/or exercise alone eligible provided meet eligibility criterion ) Participant take following medication within past 3 month : A thiazolidinedione ( e.g . pioglitazone [ Actos ] rosiglitazone [ Avandia ] ) , A biguanide ( e.g . metformin [ Glucophage , Glumetza , Fortamet , Riomet ] proguanil [ Paludrine ] ) A combination drug contain one agent ( brand name include : ACTOplus Met , Avandamet , Avandaryl , Duetact , Glucovance , Invokamet , Janumet , Jentadueto , Komboglyze , Metaglip , PrandiMet , Synjardy , Xigudo ) Participant currently take strong CYP2C8 inhibitor ( e.g . gemfibrozil [ Lopid ] ) Participant currently take enzyme inducer CYP2C8 ( carbamazepine [ Carbatrol , Epitol , Equetro , Tegretol ] cortisol [ Hydrocortisone ] ; dexamethasone [ Decadron ] ; phenobarbital [ Luminal Sodium ] ; phenytoin [ Dilantin , Phenytek , Novaplus Phenytoin Sodium ] ; primidone [ Mysoline ] ; rifampin [ Rifadin , Rimactane ] ; rifapentine [ Priftin ] ; secobarbital [ Seconal ] ) Participant currently take topiramate ( Topamax ) commonly use epilepsy prevent migraine carbonic anhydrase inhibitor ( e.g . zonisamide [ Zonegran ] ; acetazolamide [ Diamox Sequels ] ; dichlorphenamide [ Keveyis , Daranide ] ) Participant currently take cationic drug ( e.g . amiloride [ Midamor ] ; cimetidine [ Tagamet ] ; digoxin [ Lanoxin , Digitek , Digox ] ; morphine [ Roxanol , Duramorph , Kadian , MS Contin ] ; procainamide [ Pronestyl , Procanbid ] ; quinidine [ Quinidex , Cardioquin , QuinG , Quinora ] ; quinine [ Qualaquin , Quinamm , Quiphile ] ; ranitidine [ Zantac , Deprizine , Gabitidine ] ; triamterene [ Dyrenium ] ; trimethoprim [ Proloprim , Trimpex , Primsol ] ; vancomycin [ Vancocin , Vancoled ] ) Participants take another investigational agent Participant history allergic reaction attribute compound similar chemical biologic composition ACTOplus Met XR Participant contraindication biopsy Participants history congestive heart failure New York Heart Association ( NYHA ) class III IV functional status exclude Participant history liver disease Participant &gt; Common Terminology Criteria Adverse Events ( CTCAE ) grade 1 limb edema ( 5 10 % interlimb discrepancy volume circumference point great visible difference ; swell obscuration anatomic architecture close inspection ) Participant history hypoglycemia Participant active alcoholic consumes excessive amount alcohol per follow definition : Female : More 3 drink day total seven drink week Male : More 4 drink day total 14 drink week 1 drink = Beer : 12 oz . ( 1 standard size bottle ) Wine : 5 oz . ( one standard glass ) Spirits : 6 oz . ( one mixed drink one 1.5 fluid oz . shot ) Participant history macular edema Participant history bladder cancer ( include situ bladder cancer ) Participant history invasive cancer ( nonmelanoma skin cancer cervical cancer situ ) active within 18 month prior baseline study visit ; ( participant history cancer curatively treat without evidence recurrence 18 month prior baseline study visit consider eligible ) Uncontrolled intercurrent illness include , limited , ongoing active infection , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Participant pregnant , breast feeding planning become pregnant ; ( participant childbearing potential regardless method birth control must negative pregnancy test baseline ; woman consider childbearing potential hysterectomy , bilateral oophorectomy , &gt; 55 year age &gt; = 2 year amenorrhea ) Breastfeeding discontinue mother treated ACTOplus meet XR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>